These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1376 related articles for article (PubMed ID: 18809817)

  • 1. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
    J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.
    Rodríguez-Baño J; Picón E; Gijón P; Hernández JR; Ruíz M; Peña C; Almela M; Almirante B; Grill F; Colomina J; Giménez M; Oliver A; Horcajada JP; Navarro G; Coloma A; Pascual A;
    Clin Infect Dis; 2010 Jan; 50(1):40-8. PubMed ID: 19995215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
    Azap OK; Arslan H; Serefhanoğlu K; Colakoğlu S; Erdoğan H; Timurkaynak F; Senger SS
    Clin Microbiol Infect; 2010 Feb; 16(2):147-51. PubMed ID: 19689464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection.
    Rodríguez-Baño J; Alcalá J; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    J Antimicrob Chemother; 2009 Apr; 63(4):781-4. PubMed ID: 19223299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
    Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
    Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Ena J; Arjona F; Martínez-Peinado C; López-Perezagua Mdel M; Amador C
    Urology; 2006 Dec; 68(6):1169-74. PubMed ID: 17169640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
    Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.
    Oteo J; Orden B; Bautista V; Cuevas O; Arroyo M; Martínez-Ruiz R; Pérez-Vázquez M; Alcaraz M; García-Cobos S; Campos J
    J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.
    Oteo J; Bautista V; Lara N; Cuevas O; Arroyo M; Fernández S; Lázaro E; de Abajo FJ; Campos J;
    J Antimicrob Chemother; 2010 Nov; 65(11):2459-63. PubMed ID: 20851815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
    Lagacé-Wiens PR; Nichol KA; Nicolle LE; DeCorby M; McCracken M; Mulvey MR; Zhanel GG
    J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157
    [No Abstract]   [Full Text] [Related]  

  • 17. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.
    Pullukcu H; Tasbakan M; Sipahi OR; Yamazhan T; Aydemir S; Ulusoy S
    Int J Antimicrob Agents; 2007 Jan; 29(1):62-5. PubMed ID: 17189097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection.
    van der Starre WE; van Nieuwkoop C; Paltansing S; van't Wout JW; Groeneveld GH; Becker MJ; Koster T; Wattel-Louis GH; Delfos NM; Ablij HC; Leyten EM; Blom JW; van Dissel JT
    J Antimicrob Chemother; 2011 Mar; 66(3):650-6. PubMed ID: 21123286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain.
    Gobernado M; Valdés L; Alós JI; García-Rey C; Dal-Ré R; García-de-Lomas J;
    Rev Esp Quimioter; 2007 Mar; 20(1):68-76. PubMed ID: 17530038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular epidemiology of multiresistant Escherichia coli isolates from community-onset urinary tract infections in Cornwall, England.
    Woodford N; Kaufmann ME; Karisik E; Hartley JW
    J Antimicrob Chemother; 2007 Jan; 59(1):106-9. PubMed ID: 17090553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.